Clinical Research

Recently Completed Genitourinary Oncology Projects

Prostate Cancer

Protocol ID: 01-045

• Predicting Outcomes in Prostate Cancer: How Many More Nomograms Do We Need?
  Robert Ross, MD, and Philip Kantoff, MD. Journal of Clinical Oncology Vol. 25, No. 24, pp 3563-3564, 2007.
• Autoantibody Signatures in Prostate Cancer
  Philip Kantoff, MD. New England Journal of Medicine Vol. 357 No. 12, pp 1224-1235, 2005.
• Response to low dose ketoconazole and subsequent dose escalation to high does ketoconazole in patients with androgen independent prostate cancer
  Mari Nakabayashi, MD, William Oh, MD, and Philip Kantoff, MD. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S.
• Correlation of prostate-specific antigen (PSA) levels and survival in men with bone metastatic hormone-refractory prostate cancer (HRPC) and normal alkaline phosphatase (ALK)
  Wanling Xie, Mari Nakabayashi, MD, and William Oh, MD. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S.
• Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (HRPC)
  Mari Nakabayashi, MD, Oliver Sartor, MD, Robert Ross, MD, and William Oh, MD. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S.
• Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
  Mari Nakabayashi, MD, Oliver Sartor, MD, Mary Ellen Taplin, MD, and William Oh, MD. British Journal of Urology Vol. 96, pp 783-786. 2005.
• An overview of chemotherapy trials and recurrent nonmetastatic prostate cancer
  William Oh, MD. The Journal of Urology Vol. 172, pp S34-S37. 2004.
• Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer
  Mari Nakabayashi, Jonathan Ling, Wanling Xie, Meredith Regan, and William Oh, MD. Cancer J Vol 13. No. 2, pp. 125-129. 2007.

Protocol ID: 01-058

• Response to low dose ketoconazole and subsequent dose escalation to high does ketoconazole in patients with androgen independent prostate cancer
  Mari Nakabayashi, MD, William Oh, MD, and Philip Kantoff, MD. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S.

Protocol ID: 03-317

• Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes
  William Oh, MD, and Philip Kantoff, MD. Urology Vol 67, No. 6, pp 1235-1240, 2006.

Protocol ID: 04-375

• The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
  Mari Nakabayashi, MD, and William Oh, MD. Cancer Vol 109 No. 6. 2007.